2018 Congress Meeting

July 27, 2018 to July 29, 2018

Hyatt Regency Tamaya Resort and Spa

The American Society for Preventive Cardiology (ASPC) is on the move to embrace our growing national membership by changing the location of the 2018 Congress on CVD Prevention to beautiful New Mexico.

The ASPC is also bringing the 2018 Congress back to the month of July to align better with attendees’ schedules.  We encourage you to come along for the ride as the ASPC soars to new heights.

The ASPC's 2018 Congress on CVD Prevention being held at the stunning Hyatt Regency Tamaya Resort on the Rio Grande will feature innovative education, ground-breaking science and interactive discussions with top prevention experts. Attendees will have the opportunity to network with faculty and peers, and will leave with practical and useful information to use in clinical practice.

Reasons to Attend:

  • Review the latest advances, current trends and innovative therapies
  • Cutting-edge evidence-based lectures
  • Scientific abstracts and expanded poster hall
  • Meet and learn from nationally known faculty
  • Pre-congress advanced course on preventive cardiology
  • Earn CME/CE credits


Cancellation Policy: 
A written notice of cancellation must be received by June 27, 2018 in order to receive a refund. Cancellations received prior to this date will be honored minus a $75 administration fee. Refunds will not be honored after June 27, 2018. Telephone cancellations cannot be accepted. Cancellation refunds will be processed within 30 days after the conclusion of the Conference.

By registering for the 2018 ASPC Congress, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By allowing an exhibitor to scan the conference badge, attendee understands, agrees and consents to the sharing of attendee’s contact information with the company that scanned the conference badge.

By registering for this Conference, I also give ASPC the right to publish all photos, videos, etc. taken at this Conference.


2018 ASPC Experts Course Agenda (PDF)

2018 Congress on CVD Prevention Agenda (PDF)



1:00 – 1:10 PM Welcome and Overview
1:10 – 1:25 PM Pre-test via Audience Response System
1:25 – 1:55 PM Familial Hypercholesterolemia and the use of PCSK9 Monoclonal Antibodies - Peter Toth, MD, PhD, FASPC
1:55 – 2:25 PM Hypertriglyceridemia: Is it a CV Risk factor and How Can it Be Treated? - Seth Baum, MD, FASPC
2:25 – 2:40 PM Refreshment Break
2:40 – 3:10 PM Integrating Advanced Lipid Testing and CV Biomarkers in Assessment and Treatment - Stephen Kopecky, MD, FASPC
3:10 – 3:40 PM ASCVD Risk Assessment: Global Risk Scoring and Evaluating for Subclinical Atherosclerosis - Nathan Wong, PhD, FASPC
3:40 – 4:10 PM State of the Art Management of Heart Failure - Douglas Schocken, MD, FASPC
4:10 – 4:40 PM Role of Inflammation in Atherogenesis - Peter Toth, MD, PhD, FASPC
4:40 – 5:00 PM Question and Answer Panel Discussion

FRIDAY, JULY 27, 2018

8:00 – 8:05 AM Welcome and Overview
8:05 – 8:35 AM State of the Art Management of Hypertension - Daniel Duprez, MD, PhD
8:35 – 9:05 AM Coronary Stenting: Is it Really Preventive? - William Boden, MD
9:05 – 9:35 AM Diagnosis and Management of Chronic Kidney Disease - Daniel Duprez, MD, PhD
9:35 – 10:05 AM Obesity and the Facilitation of Weight Loss - Jaime Almandoz, MD
10:05 – 10:25 AM Question and Answer Panel Discussion
10:25 – 10:40 AM Refreshment Break
10:40 – 11:10 AM Integrating Imaging and Stress Testing in Assessment and Treatment - Amit Khera, MD, FASPC
11:10 – 11:40 AM Intelligent Drug Choices in the Management of Non-insulin-dependent Diabetes Mellitus - Peter Wilson, MD
11:40 – 11:50 AM Question and Answer Panel Discussion
11:50 – 12:40 PM Lunch
12:40 – 1:10 PM Atrial Fibrillation: Management and Anticoagulation - Stephen Kopecky, MD, FASPC
1:10 – 1:40 PM Antiplatelet Agents in Primary and Secondary Prevention: When are They Indicated? - Peter Toth, MD, FASPC
1:40 – 1:50 PM Question and Answer Panel Discussion
1:50 – 2:20 PM Testosterone Supplementation and Risk of Cardiovascular Events – What do you Tell a Man? - Stephen Kopecky, MD, FASPC
2:20 – 2:50 PM Evaluating Chest Pain and Myocardial Ischemia in Women - Martha Gulati, MD, FASPC
2:50 – 3:00 PM Question and Answer Panel Discussion
3:00 – 3:30 PM Post-test via Audience Response System and Closing Remarks


FRIDAY, JULY 27, 2018

3:30 – 3:40 PM Welcoming Remarks
3:40 – 3:50 PM Audience Response Questions
3:50 – 4:15 PM Preventive Cardiology now and 5 years from now, a strategic vision - Sergio Fazio, MD, PhD
4:15 – 4:40 PM Keynote Address: Genetics in CVD Prevention: Insights and Opportunities - Sekar Kathiresan, MD
4:40 – 5:05 PM Charting New Territory – Inflammation as a CVD Target - Christie Ballantyne, MD
5:05 – 5:30 PM Question and Answer Panel Discussion and Audience Response Questions
5:30 – 6:30 PM Welcome Reception with Exhibitors


SESSION 2- Hypertension Guidelines
7:00 – 8:00 AM Breakfast with Exhibitors
8:00 – 8:15 AM Welcome and Audience Response Questions
8:15 – 8:40 AM AHA/ACC 2017 Hypertension Guidelines Update - William Cushman, MD
8:40 – 9:05 AM Managing Blood Pressure in Special Populations - Keith Ferdinand, MD
9:05 – 9:30 AM Achieving Blood Pressure Controls in Your Clinic – Strategies for Success - Lynne Braun, PhD, CNP
9:30 – 9:55 AM Question and Answer Panel Discussion and Audience Response Questions
9:55 – 10:10 AM Refreshment Break
SESSION 3- Cardiometabolic
10:10 – 10:20 AM Audience Response Questions
10:20 – 10:45 AM Role of SGLT2/GLP1 Agents in a Preventive Cardiologist’s Practice, a Seminal Transition in DM Management - Mikhail Kosiborod, MD
10:45 – 11:10 AM Comprehensive Approach to Lowering CVD Risk in Diabetics - Yehuda Handelsman, MD
11:10 – 11:35 AM Differentiating Antiplatelet Agents - Dr. Peter Toth, MD, PhD
11:35 AM – 11:55 PM Question and Answer Panel Discussion and Audience Response Questions
11:55 AM – 12:05 PM ASPC Annual Business Meeting
12:05 – 1:00 PM Lunch with Exhibitors
1:00 – 1:20 PM Young Investigator Presentation
1:20 – 1:40 PM Young Investigator Presentation
1:40 – 2:00 PM Young Investigator Presentation
SESSION 5 - Native American/Special Populations
2:00 – 2:10 PM Audience Response Questions
2:10 – 2:35 PM Nanette Wegner Lecture – Go Red for Women: What a Difference a Movement Makes - Lori Mosca, MD, MPH, PhD
2:35 – 3:00 PM Cardiometabolic Disease in Native American’s- Lessons from Strong Heart - Barbara Howard, PhD
3:00 – 3:25 PM Preventing and Managing Heart Failure – One Size Does Not Fit All - Clyde Yancy, MD
3:25 – 3:50 PM Panel Discussion/Question and Answer Session
3:50 – 4:05 PM Refreshment Break
SESSION 6 - Cases
4:05 – 4:15 PM Update on FH and the FIND FH Initiative - Christie Ballantyne, MD
Moderators- Christie Ballantyne, MD; Lori Mosca MD, MPH, PhD, Keith Ferdinand, MD
4:15 – 4:40 PM Case 1 (Fellow 1)
4:40 – 5:05 PM Case 2 (Fellow 2)
5:05 – 5:30 PM Case 3 (Fellow 3)
5:30 PM Adjourn

SUNDAY, JULY 29, 2018

SESSION 7 Nutrition and Lipids
7:00 – 8:00 AM Breakfast with Exhibitors
8:00 – 8:15 AM Welcome and Audience Response Questions
8:15 – 8:40 AM Dietary Fats and CVD- Calming The Controversy - JoAnn Carson, PhD
8:40 – 9:05 AM PCSK9 Inhibitors Today- When, How, and In Whom - Jennifer Robinson, MD
9:05 – 9:30 AM Re-emergence of Triglyceride Lowering- ANGPTL3, ApoC3, and Beyond - Seth Baum, MD
9:30 – 9:55 AM Question and Answer Panel Discussion and Audience Response Questions
SESSION 8 Debate Potpourri/Debate
9:55 – 10:05 AM Audience Response Questions
10:05 – 10:30 AM SCCT Lecture- What We Know and Don’t Know About Coronary Artery Calcium Imaging - Khurram Nasir, MD
10:30 – 10:55 AM Screening and Anticoagulation for Afib – New Options and Opportunities - Sana Al-Khatib, MD
10:55 – 11:10 AM Debate – Pro – Lipoprotein(a) – Should Be Measured In All Patients At Higher CVD Risk - Pat Moriarty, MD
11:10 – 11:25AM Debate – Con – Lipoprotein(a) – There is Nothing You Can Do About It So Why Measure? - Sergio Fazio, MD, PhD
11:25 – 11:40 AM Question and Answer Panel Discussion and Audience Response Questions
11:45 – 12:00 PM Wrap up and Adjourn


Experts Course Directors

Peter Toth, MD, PhD, FASPC
Preventive Cardiology Experts Course Chair
Director, Preventative Cardiology
CGH Medical Center
Sterling, IL
Professor, Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, IL
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, MI
Adjunct Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
[spacer height="20px"]

Seth Baum, MD, FASPC
Preventive Cardiology Experts Course Co-Chair
Medical Director, Women’s Preventive Cardiology
Christine E. Lynn Women’s Health and Wellness Institute
Boca Raton Regional Hospital
Co-Founder and Chief Medical Officer, MB Clinical Research
Boca Raton, FL

[spacer height="20px"]


Jaime Almandoz, MD
Assistant Professor
Division of Endocrinology
Weight Wellness Program
University of Texas Southwestern Medical Center

[spacer height="20px"]

William Boden, MD
Scientific Director, Clinical Trials Network, MAVERIC
VA New England Healthcare System
VA Boston - Jamaica Plain Campus
Professor of Medicine
Boston University School of Medicine
Boston, MA

[spacer height="20px"]

Daniel Duprez, MD, PhD
Donald and Patricia Garofalo Chair in Preventive Cardiology
Professor of Medicine/Cardiology
Director Lipid Clinic
Director of Research of the Rasmussen Center for Cardiovascular Disease Prevention
Professor Epidemiology and Community Health (School of Public Health)
Cardiovascular Division
University of Minnesota
Minneapolis, MN

[spacer height="20px"]

Martha Gulati, MD, MS
Chief of Cardiology
University of Arizona College of Medicine - Phoenix
CardioSmart for The American College of Cardiology
Phoenix, AZ

[spacer height="20px"]

Amit Khera, MD, MSc, FASPC
Director, Preventive Cardiology
UT Southwestern Medical Center at Dallas
Dallas, TX

[spacer height="20px"]

Stephen Kopecky, MD, FASPC
Professor of Medicine
Consultant, Cardiovascular Diseases and Internal Medicine
Mayo Clinic
Rochester, MN

[spacer height="20px"]

Douglas Shocken, MD, FASPC
Professor of Medicine
Duke University School of Medicine
Durham, NC
[spacer height="20px"]
Howard Weintraub, MD, FASPC
Clinical Professor of Medicine
New York University School of Medicine
Clinical Director, NYU Center for the Prevention of
Cardiovascular Disease
New York, NY
[spacer height="20px"]
Peter Wilson, MD
Professor of Medicine, Division of Cardiology
Emory University School of Medicine
Professor of Public Health, Rollins School of Public Health
Director, Epidemiology and Genomic Medicine
Atlanta VA Medical Center
Atlanta, GA
[spacer height="20px"]

Nathan Wong, PhD, FASPC
Professor and Director
Heart Disease Prevention Program, Division of Cardiology
University of California, Irvine
Irvine, CA

[spacer height="20px"] 

Congress Faculty 

Congress Directors

Amit Khera, MD, MSc, FASPC
Congress Chair
Director, Preventive Cardiology
UT Southwestern Medical Center at Dallas
Dallas, TX

[spacer height="20px"]

Seth Baum, MD, FASPC
Congress Co-Chair
Medical Director, Women’s Preventive Cardiology
Christine E. Lynn Women’s Health and Wellness Institute
Boca Raton Regional Hospital
Co-Founder and Chief Medical Officer, MB Clinical Research
Boca Raton, FL

[spacer height="20px"]


Sana Al-Khatib, MD, MHS
Professor of Medicine
Duke University Medical School
Durham, NC
[spacer height="20px"]

Christie Ballantyne, MD
Chief of Cardiology
Vice Chair of Research
Professor of Medicine
Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Methodist DeBakery Heart and Vascular Center
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
Houston Methodist Hospital
Houston, TX
[spacer height="20px"]

Lynne Braun, PhD, CNP
Professor, Department of Adult Health and Gerontological Nursing
College of Nursing
Rush University
Nurse Practitioner, Rush Heart Center for Women
Chicago, IL
[spacer height="20px"]

JoAnn Carlson, PhD
Professor of Clinical Nutrition
UT Southwestern Medical Center
Dallas, TX

[spacer height="20px"]

William Cushman, MD
Professor of Preventive Medicine, Medicine, and Physiology
University of Tennessee College of Medicine
Chief, Preventive Medicine Section (111Q)
Veterans Affairs Medical Center
Memphis, TN

[spacer height="20px"]

Sergio Fazio, MD, PhD
The William and Sonja Connor
Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR

[spacer height="20px"]

Keith Ferdinand, MD
Professor of Clinical Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, LA

[spacer height="20px"]

Yehuda Handelsman, MD
Medical Director and Principal Investigator
Metabolic Institute of America
Tarzana, CA

[spacer height="20px"]

Barbara Howard, PhD
Senior Scientist, Health Research Institute
Professor of Medicine, Georgetown University
Hyattsville, MD

[spacer height="20px"]

Sekar Kathiresan, MD
Director, Center for Genomic Medicine
Massachusetts General Hospital
Director of Cardiovascular Disease Initiative, Broad Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

[spacer height="20px"]

Mikhail Kosiborod, MD
Professor of Medicine
University of Missouri-Kansas City School of Medicine
Missouri, MO

[spacer height="20px"]

Patrick Moriarty, MD
Profession, Department of Internal Medicine
Director, Clinical Pharmacology
University of Kansas Medical Center
Kansas City, KS

[spacer height="20px"]

Lori Mosca, MD, MPH, PhD
Professor of Medicine, Columbia University Medical Center
Director of Preventive Cardiology, New York-Presbyterian Hospital
New York, NY

[spacer height="20px"]

Khurram Nasir, MD, MPH, MSc, FACC, FAHA, FSCCT

Section of Cardiovascular Medicine, Yale University School of Medicine
Director Population Health & Health Systems Research
Center for Outcomes Research and Evaluation
Yale New Haven Health System
New Haven, CT

[spacer height="20px"]

Jennifer Robinson, MD, MPH
Professor, Director, Preventive Intervention Center
College of Public Health
University of Iowa
Iowa City, IA

[spacer height="20px"]


The Hyatt Regency Tamaya Resort is sold out for the evening of Saturday, July 28th. We apologize for this inconvenience. The ASPC has arranged an overflow hotel at the Santa Ana Star Hotel, only two miles from the Tamaya Resort. A free shuttle is available every morning and evening for ASPC Congress Attendees for ease of getting to and from the Congress.

Santa Ana Hotel
54 Jemez Canyon Dam Rd.
Santa Ana Pueblo, NM 87004
Reservation Number: 1-844-466-2378
Please reference ASPC or Group code 336


Hyatt Regency Resort and Spa NMHyatt Regency Tamaya Resort and Spa
1300 Tuyuna Trail
Bernalillo, NM 87004

Join us at the Hyatt Regency Tamaya Resort and Spa from July 27-29, 2018, and enjoy the stunning Southwestern beauty of New Mexico. Nestled on 550 acres of the Native American Santa Ana Pueblo, the Hyatt Regency Tamaya Resort and Spa is the perfect home base to explore Santa Fe and Albuquerque. At Tamaya, you can relax and indulge yourself at the award-winning Tamaya Mist Spa and Salon, hit the links at the championship Twin Warriors golf course, or take a horseback ride on a rescue horse at the Stables at Tamaya. A 10% discount is being offered at the Spa and Salon, as well as, trail rides at the Stables.  A 15% discount is being offered for Green Fees at the Twin Warriors golf course.

Congress attendees receive discounted room reservations starting at $199 per night, exclusive of state and local taxes, and resort fees have been waived. Reservations are available until the cutoff date of July 5, 2018 or until the room block is full. To make your hotel reservations online click here or
call 505-867-1234 and reference the 2018 ASPC CVD Conference.  Complimentary self-parking, a 24 hour fitness center and guestroom internet are also provided.

Hot Air Balloons New Mexico
Horseback Riding


Abstract Submission 

The 2018 ASPC Abstract Committee invites the submission of abstracts to be presented at the 2017 Congress on Cardiovascular Disease Prevention July 27-29, 2018, at the Hyatt Regency Tamaya Resort and Spa. Submitted abstracts will be considered for the poster hall and the top three Young Investigator abstracts with be picked for an oral presentation during the abstract session at the meeting. 

All abstracts must be submitted online via the ASPC abstract submission website using the online submission form. Please be sure to read all instructions, information, and policies closely. 

Important Dates 

Abstract Submission Deadline
Tuesday, May 15, 2018
5:00 p.m. EST

Abstract Acceptance Notification
Friday, June 1, 2018

Presenting Author Registration Deadline for CVD Prevention Conference
Friday, June 22, 2018


ASPC Young Investigator Awards 
Young Investigators (in training students, residents, and fellows or members in practice for <5 years) will have the chance to compete for the ASPC's Young Investigator Award. Cash prizes of $750, $500, and $250 will be presented to the top three Young Investigator Winners. In addition, the top three Young Investigator abstracts with be selected for an oral presentation. 

Awards Disclaimer 
If you are the recipient of one of our Young Investigator Awards, you are required to register and attend the 2017 Congress on Cardiovascular Disease Prevention, as well as attend all abstract-related responsibilities. These responsibilities include hanging your poster in the Poster Hall, standing by your poster in the poster hall during the designated time, as well as attend the oral presentation session. If you fail to attend these events, your prize and travel money could be revoked and you could be blacklisted from future abstract awards.  

Presentation Methods 

All accepted abstracts will be displayed in the Poster Hall. 

The ASPC Abstract Committee will select three Young Investigator abstracts to be presented during the oral abstract session on Saturday, July 28, 2018. Authors will have 20 minutes to present their research (15 minutes to present and 5 minutes for questions and answers). 

Abstract Submission Instructions 

Please read through the submission instructions below before preparing your abstract: 

  1. Read the General Information and Policies for the submission of an abstract. 
  2. Write your abstract, following the Abstract Guidelines. 
  3. Select a Topic that best relates to your abstract. 
  4. Review the Acceptance and Presentation Process for abstracts. 
  5. Submit your abstract through the Online Abstract Submission Form button. 
  6. Register to attend the 2018 Congress on Cardiovascular Disease Prevention (ASPC staff will contact you with a meeting registration form to register for the meeting if your abstract has been approved). 

General Information and Policies 

  • You may complete your abstract submission over multiple sessions. As you will see, there will be a point in the process when you MUST finalize your abstract and make a FINAL submission. Please note that if you do not mark your abstract as complete and make a FINAL submission, it will NOT be considered. Take note of any deadlines under the appropriate call for abstracts and be sure to complete the process before that date. 
  • Do not CREATE your abstract in the submission system, but rather create your abstract in a separate Word document and COPY and PASTE it into the abstract submission system. This way, you will not have lost your abstract in the event of disconnection from the Internet, etc. Be sure to check for errors when pasting. Certain special characters may be changed by the browser. 
  • If you are currently a member of the ASPC, we will prefill your address information for you in the online submission form based on your current account information profile. Note that changes made here will apply to your abstract only and WILL NOT BE APPLIED to your ASPC member record or account. 
  • The lead author must register for the 2018 Congress on Cardiovascular Disease Prevention to ensure his or her abstract(s) are included in onsite materials. Deadline for author registration is Friday, June 15, 2018. Lead authors MUST BE registrants at the ASPC Congress on Cardiovascular Disease Prevention. Authors who are not members of the ASPC must pay the non-member registration fee or can apply for membership here. Young Investigator lead authors with accepted abstracts will receive complimentary registration to the Conference. 
  • To submit an abstract, all of the authors listed on the abstract must approve the final version. In addition, each author listed on the abstract should have made a substantial contribution to it, such as 1) contributing to the conception and design of the study and the acquisition of data; 2) analysis and interpretation of the data; and/or 3) drafting the poster and/or revising it critically for important intellectual content. Full disclosures must be provided for each author. These requirements are taken seriously by ASPC and any failure to fully comply with these requirements may result in an abstract being withdrawn from the ASPC abstracts program. 
  • It is the responsibility of the lead author to ensure that his or her abstract is submitted correctly. 
  • Abstracts will be reviewed by the appointed ASPC Abstracts Review Committee Member. 
  • Faxed, emailed or mailed hard-copy abstracts or abstracts sent on a CD/disc WILL NOT be accepted. If you are unable to submit via the website, please contact the ASPC Annual Meeting Staff:

    Contact: Stacy Manthos 
    Phone: 904-217-7407 


The ASPC will not be responsible for abstract submissions not received via the website or for submission errors caused by Internet service outages, hardware or software delays, power outages, or unforeseen events. 

Abstract Guidelines 

Content Guidelines 

Abstracts for poster entries submitted for competition can only be accepted electronically and must adhere to the following guidelines: 

  • Abstracts are limited to 350 words. (Word count excludes the abstract title, author names, and affiliations.) 
  • Abstracts must be divided into sections: Title, Background/Synopsis, Objectives/Purpose, Design/Methods, Results, and Conclusion that states the importance and potential implications of the observations. 
  • Abstracts must be proofread carefully to avoid errors before submission. 
  • Abstracts must contain generic drug names only. 
  • Abstracts must be submitted in clear English with accurate grammar and spelling of a quality suitable for publication. 
  • Lead and secondary authors must disclose all financial relationships. 
  • Any funding support for the research must be disclosed. 
  • Encore research is eligible for submission but the original date and location of presentation of the research must be disclosed in the application. 


The purpose of the abstract is to define the precise subject of the presentation to an audience. Below you will find a checklist for abstract preparation. All abstracts are considered equally for selection, and the quality of the abstract is the single most important factor in the Committee's decision. 

You will be asked for the following: 

  • Title 
  • Background/Synopsis - A concise description of your subject matter and prior work in this area. 
  • Objective/Purpose - The question your material answers or the hypothesis that it tests. 
  • Methods - The experimental design or technique employed. 
  • Results - Outcomes & measurements, with statistical significance, if appropriate 
  • Conclusion - Conclusions, clinical pertinence, and value or for Workshops and Presentations, the prevailing point of view. 
  • Proofread - Make sure to proofread your abstract. Misspellings and typographical errors reflect badly on your scientific work. Prepare to substitute plain text for special characters as these characters may not be rendered reliably (i.e., plus or minus for ±, alpha for a etc.) 
  • Authors - For each author you must provide first and last name, city and state as well as preliminary financial disclosure information. If you would like to be considered for oral presentation, the Primary Author should also upload a brief paragraph describing their qualifications in the chosen subject area and/or a CV. 
  • Supplemental Materials - Supplementary materials (figures, tables, illustrations) will not be published along with abstracts on the CLC website. If you do have supporting materials, we will include a link to them in the published abstract, but they will be housed on the ASPC website for view. 

Abstract Submission Topics 

To ensure your abstract receives proper consideration, the abstract must relate to an appropriate topic in the field of Cardiology and cardiovascular disease prevention. Abstract authors will be required to indicate which topic BEST matches the content of their abstract. Topics for the 2017 ASPC Congress on Cardiovascular Disease Prevention are: 

  • ASCVD Risk Factors 
  • ASCVD Risk Assessment 
  • ASCVD Risk Reduction 
  • ASCVD Prevention – Primary and Secondary 
  • Preventive Cardiology Best Practices – clinic operations, team approaches, outcomes research 
  • Metabolic Syndrome 
  • Diabetes 
  • Obesity 
  • Novel Biomarkers 
  • Pharmacologic Therapy 
  • Nutrition/Exercise 
  • ASCVD in Women 
  • ASCVD in Special Populations 
  • Heart Failure 
  • Ischemic Stroke 
  • Peripheral Artery Disease 
  • Alterative and Complimentary Approaches 
  • Rehabilitation 
  • Other 

If you do not see an appropriate topic listed above that best relates to your abstract, please contact the ASPC office at or call 904-217-7407. 

Acceptance and Presentation Process 

Abstract grading is blinded and abstracts are pre-screened and selected by ASPC judges on the basis of quality and merit. You will be notified by Friday, June 1, 2018, if your poster is accepted. All lead poster authors are required to register for the 2018 Congress on Cardiovascular Disease Prevention July 27-29, 2018, at the Hyatt Regency Tamaya Resort and Spa to field questions from ASPC meeting attendees. 

*Expenses related to airfare, lodging, and social events/guest fees are the responsibility of the presenter. Special programs may be available for trainees, fellows, and young investigators — see Young Investigator Award. 

Poster guidelines will be provided to lead authors by May 9, 2018. 



Held at the Hyatt Regency Tamaya Resort & Spa in Santa Ana Pueblo, New Mexico, the 2018 Annual Meeting is your opportunity to interact and market your product, device or service to the American Society for Preventive Cardiology's audience. As an exhibitor, increase your presence at this meeting by taking advantage of exhibitor-only sponsorship opportunities and showcase what your company has to offer. Sponsorships and exhibits are available in different levels to guarantee your company's maximum exposure.

View the Exhibitor Prospectus

Lead Retrieval Order Form

2018 ASPC Congress Service Kit

For additional Sponsorship opportunities, Satellite Symposium information, or Exhibit Theater opportunities contact Maggie Kincaid.

Maggie Kincaid
Phone: (904) 233-0282

Saturday, July 28, 2018

Hyatt Regency Tamaya Resort and Spa
Tamaya Ballroom FGH
Santa Ana Pueblo, NM

7:00 pm - 7:30 pm  Registration and Dinner

7:30 pm - 9:00 pm  CME-certified Symposium

Program Overview

As clinical data emerge regarding the benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, obtaining access to these agents remains a barrier to their use. Given the high prevalence of patients on statin therapy who fail to meet low-density lipoprotein cholesterol (LDL-C) target goals, continuing education is crucial regarding the latest clinical advances and recommendations for the use of PCSK9 inhibitors, as well as practical strategies to gain access to these agents to improve patient outcomes. This educational activity will feature a panel of experts who will review the latest recommendations for the use of PCSK9 inhibitors in prevention and the impact of their use on cardiovascular outcomes. They will also assess the latest data on the benefits and safety of achieving low LDL-C goals, as well as detail practical strategies to improve access to treatment. Clinical cases will be presented to highlight the key educational objectives.

Activity Chair:

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA

Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Bellevue Hospital Lipid Clinic
New York, NY


Michael H. Davidson, MD, FACC, FACP, FNLA
Director of the Lipid Clinic
The University of Chicago
Pritzker School of Medicine
Chicago, IL

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
President-Elect, Southeast Lipid Association
Medical University of South Carolina
Charleston, SC


Product Theater Workshops

Saturday, July 28

Wolf Room
12:05-1:00 PM

Evolving Clinical Development

This program will discuss recent data from the ongoing JARDIANCE clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE.

Attendees will also have the opportunity to ask the faculty questions about the data presented.

Presenter: James H. O’Keefe, MD
Director of Wellness Center
Saint Luke’s of Kansas City
Professor of Medicine
University of Missouri-Kansas City
Kansas City, MO

Sponsored by Boehringer Ingelheim and Lilly USA

Saturday, July 28

Puma Room
12:05-1:00 PM

Severe Hypertriglyceridemia & Pancreatitis: Including Familial Chylomicronemia Syndrome (FCS) in Your Differential Diagnosis

Presenter: Michael Miller, MD, FACC, FAHA
Professor of Medicine, Cardiology
Director, Center for Preventive Cardiology
University of Maryland School of Medicine

Sponsored by Ackea Therapeutics